300485 赛升药业
开盘竞价 05-18 09:30:00
资讯
新帖
简况
股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%
证券之星 · 04:08
股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%
赛升药业：公司在研项目K11预计2026年将完成临床研究
证券之星 · 05-15 16:00
赛升药业：公司在研项目K11预计2026年将完成临床研究
股市必读：赛升药业(300485)股东户数3.08万户，较上期减少12.37%
证券之星 · 05-08
股市必读：赛升药业(300485)股东户数3.08万户，较上期减少12.37%
每周股票复盘：赛升药业（300485）股东户数增8.67%
证券之星 · 05-03
每周股票复盘：赛升药业（300485）股东户数增8.67%
赛升药业：与北京亦庄国际共参与两支基金设立
证券之星 · 04-30
赛升药业：与北京亦庄国际共参与两支基金设立
赛升药业：公司参与设立基金的投资方向为生命科学及大健康产业相关领域
证券之星 · 04-29
赛升药业：公司参与设立基金的投资方向为生命科学及大健康产业相关领域
赛升药业(300485.SZ)发布一季度业绩，归母净利润466.33万元，下降88.33%
智通财经 · 04-28
赛升药业(300485.SZ)发布一季度业绩，归母净利润466.33万元，下降88.33%
股市必读：赛升药业（300485）4月21日披露最新机构调研信息
证券之星 · 04-22
股市必读：赛升药业（300485）4月21日披露最新机构调研信息
赛升药业：公司将全力做好各项经营工作
证券日报网 · 04-21
赛升药业：公司将全力做好各项经营工作
赛升药业：截至2026年4月10日，公司股东户数为35194
证券之星 · 04-14
赛升药业：截至2026年4月10日，公司股东户数为35194
赛升药业：公司在研项目K11预计2026年将完成临床研究
证券之星 · 04-14
赛升药业：公司在研项目K11预计2026年将完成临床研究
赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%
证券之星 · 04-07
赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%
股市必读：赛升药业（300485）4月3日董秘有最新回复
证券之星 · 04-07
股市必读：赛升药业（300485）4月3日董秘有最新回复
图解赛升药业年报：第四季度单季净利润同比下降227.07%
证券之星 · 03-30
图解赛升药业年报：第四季度单季净利润同比下降227.07%
赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元
智通财经 · 03-30
赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元
太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点
投资观察 · 03-28
太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点
赛升药业：截至2026年3月20日，公司股东户数为32211
证券之星 · 03-26
赛升药业：截至2026年3月20日，公司股东户数为32211
赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%
证券之星 · 03-20
赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%
赛升药业(300485.SZ)子公司撤回一项药品注册申请
智通财经 · 03-20
赛升药业(300485.SZ)子公司撤回一项药品注册申请
太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎
投资观察 · 03-16
太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎
暂无数据
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":10.16,"timestamp":1779067098000,"preClose":10.16,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":274000000,"shares":482000000,"eps":-0.0431,"marketStatus":"开盘竞价","change":0,"latestTime":"05-18 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":10.16,"askSize":26,"bidPrice":10.16,"bidSize":26,"shortable":0,"etf":0,"ttmEps":-0.0431,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":1,"adr":0,"adjPreClose":10.16,"symbolType":"stock","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":11.18,"lowLimit":9.14,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.45,"roa":"--","roe":"0.14%","epsLYR":0.03,"committee":-0.373494,"marketValue":4894000000,"turnoverRate":0,"status":2,"floatMarketCap":2782000000},"requestUrl":"/m/hq/s/300485/tweets","defaultTab":"tweets","newsList":[{"id":"2636153016","title":"股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636153016","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636153016?lang=zh_cn&edition=full","pubTime":"2026-05-18 04:08","pubTimestamp":1779048493,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，赛升药业报收于10.16元，下跌1.74%，换手率1.83%，成交量5.02万手，成交额5137.69万元。来自股本股东变化：截至2026年5月8日，公司股东户数环比下降1.64%，户均持股上升至1.59万股，呈现筹码集中趋势。股本股东变化股东户数变动近日赛升药业披露，截至2026年5月8日公司股东户数为3.03万户，较4月30日减少505.0户，减幅为1.64%。户均持股数量由上期的1.56万股增加至1.59万股，户均持股市值为17.02万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0239","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635011237","title":"赛升药业：公司在研项目K11预计2026年将完成临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2635011237","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635011237?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:00","pubTimestamp":1778832025,"startTime":"0","endTime":"0","summary":"赛升药业回复：您好，公司在研项目K11预计2026年将完成临床研究，2027年提交上市注册申请。药品研发需经多期临床，周期长、风险高，易受技术、审批、政策等影响，临床研究存在结果不及预期甚至临床研究失败的风险，后续能否获得批准存在不确定性，敬请注意投资风险。有关在研项目具体进展情况可查阅巨潮资讯网公司《2025年年度报告》以及关注后续临时公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500026447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0046","BK0028","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120169","title":"股市必读：赛升药业(300485)股东户数3.08万户，较上期减少12.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633120169?lang=zh_cn&edition=full","pubTime":"2026-05-08 02:07","pubTimestamp":1778177230,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，赛升药业报收于10.78元，下跌1.28%，换手率2.57%，成交量7.04万手，成交额7618.03万元。来自股本股东变化：截至2026年4月30日，赛升药业股东户数环比下降12.37%，户均持股上升至1.56万股。股本股东变化股东户数变动近日赛升药业披露，截至2026年4月30日公司股东户数为3.08万户，较4月10日减少4355.0户，减幅为12.37%。户均持股数量由上期的1.37万股增加至1.56万股，户均持股市值为17.04万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800002067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0046","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670944","title":"每周股票复盘：赛升药业（300485）股东户数增8.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670944?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:56","pubTimestamp":1777762573,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，赛升药业报收于10.91元，较上周的11.37元下跌4.05%。本周，赛升药业4月28日盘中最高价报12.14元。股本股东变化股东户数变动截至2026年4月10日，赛升药业股东户数为3.52万户，较3月31日增加2808.0户，增幅8.67%。业绩披露要点财务报告赛升药业2026年一季报显示，一季度公司主营收入9043.89万元，同比下降2.27%；归母净利润466.33万元，同比下降88.33%；扣非净利润1022.51万元，同比上升759.26%；负债率4.76%，投资收益197.19万元，财务费用2.89万元，毛利率68.11%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0046","BK0028","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631063770","title":"赛升药业：与北京亦庄国际共参与两支基金设立","url":"https://stock-news.laohu8.com/highlight/detail?id=2631063770","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631063770?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:51","pubTimestamp":1777553467,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月29日在投资者关系平台上答复投资者关心的问题。你们共同投资的北京亦庄二期生物医药产业投资基金贵司占股31%，北京亦庄国际占比30%收益如何？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000065930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","BK0012","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631338552","title":"赛升药业：公司参与设立基金的投资方向为生命科学及大健康产业相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2631338552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631338552?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:38","pubTimestamp":1777433904,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月29日在投资者关系平台上答复投资者关心的问题。收益情况可查阅巨潮资讯网公司《2025年年度报告》“第八节 财务报告 七、合并财务报表项目注释 10、长期股权投资”及 十、在其他主体中的权益 2、在合营企业或联营企业中的权益”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900037837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0239","BK0012","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630795873","title":"赛升药业(300485.SZ)发布一季度业绩，归母净利润466.33万元，下降88.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630795873","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630795873?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:47","pubTimestamp":1777366064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2026年第一季度报告，该公司营业收入为9043.89万元，同比增长0.00%。归属于上市公司股东的净利润为466.33万元，同比减少88.33%。归属于上市公司股东的扣除非经常性损益的净利润为1022.51万元，同比增长759.26%。基本每股收益为0.0097元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"530716c61aaa22cfcffdb04a123fa588","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054623","title":"股市必读：赛升药业（300485）4月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629054623?lang=zh_cn&edition=full","pubTime":"2026-04-22 02:38","pubTimestamp":1776796690,"startTime":"0","endTime":"0","summary":"截至2026年4月21日收盘，赛升药业报收于11.73元，下跌2.33%，换手率3.63%，成交量9.93万手，成交额1.17亿元。来自机构调研要点：公司主营业务毛利率达65.1%，虽因高研发投入导致净利润小幅下降，但主业本身盈利，多个在研项目进入临床阶段。答：尊敬的投资者您好，根据公司2025年年度报告显示，公司2025年主营业务收入为3.98亿元，营业成本为1.39亿元，主营业务毛利率为65.1%。但受研发高投入及对外投资等因素影响，公司整体净利润小幅减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200006378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300485","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629525039","title":"赛升药业：公司将全力做好各项经营工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2629525039","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629525039?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:39","pubTimestamp":1776771540,"startTime":"0","endTime":"0","summary":"当前估值水平受多重因素影响，公司将通过扎实经营业绩、加强投资者沟通等方式，推动市场价值合理反映企业基本面。目前公司生产经营各项工作均有序进行，公司将继续坚持踏实做好主业，以长期、稳定、优良的业绩回报股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-21/doc-inhvhmhw6111100.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-21/doc-inhvhmhw6111100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0028","BK0046","300485","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627191404","title":"赛升药业：截至2026年4月10日，公司股东户数为35194","url":"https://stock-news.laohu8.com/highlight/detail?id=2627191404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627191404?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:57","pubTimestamp":1776157024,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2026年4月10日公司的股东人数是多少?谢谢赛升药业回复：您好，截至2026年4月10日，公司股东户数为35194。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400026811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300485","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627419541","title":"赛升药业：公司在研项目K11预计2026年将完成临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627419541","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627419541?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:51","pubTimestamp":1776156673,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业04月14日在投资者关系平台上答复投资者关心的问题。同时贵公司是否还有其他创新药项目赛升药业回复：您好，公司在研项目K11预计2026年将完成临床研究，2027年提交上市注册申请。公司在研项目属于1类新药的有安替安吉肽、血管生成抑肽、GGE-3、NeoAB33等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400026629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","BK0012","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625939502","title":"赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939502","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939502?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:31","pubTimestamp":1775554260,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，赛升药业报收于11.7元，较前一交易日上涨3.72%，最新总市值为56.35亿元。该股当日开盘11.36元，最高11.71元，最低10.85元，成交额达2.45亿元，换手率为7.89%。近日，北京赛升药业股份有限公司子公司沈阳君元药业有限公司收到辽宁省药品监督管理局换发的《药品生产许可证》，许可证有效期至2031年3月24日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0239","300485","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625785606","title":"股市必读：赛升药业（300485）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625785606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625785606?lang=zh_cn&edition=full","pubTime":"2026-04-07 03:22","pubTimestamp":1775503333,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，赛升药业报收于11.28元，下跌3.75%，换手率7.85%，成交量21.5万手，成交额2.48亿元。董秘最新回复投资者： 请问截至2026年3月 31日公司的股东总数是多少？谢谢董秘： 您好，截至2026年3月31日，公司股东户数为32386。交易信息汇总资金流向4月3日主力资金净流出485.74万元，占总成交额1.96%；游资资金净流出2079.26万元，占总成交额8.37%；散户资金净流入2564.99万元，占总成交额10.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0239","BK0046","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313130","title":"图解赛升药业年报：第四季度单季净利润同比下降227.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313130","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623313130?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:33","pubTimestamp":1774863209,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业2025年年报显示，当年度公司主营收入4.05亿元，同比下降2.82%；归母净利润1457.1万元，同比上升121.16%；扣非净利润-2699.04万元，同比下降329.51%；其中2025年第四季度，公司单季度主营收入9609.13万元，同比上升2.66%；单季度归母净利润-3728.86万元，同比下降227.07%；单季度扣非净利润-2276.76万元，同比下降293.4%；负债率4.93%，投资收益2853.87万元，财务费用-85.25万元，毛利率65.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318821","title":"赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318821","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623318821?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:57","pubTimestamp":1774861044,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2025年年度报告，该公司营业收入为4.05亿元，同比减少2.82%。归属于上市公司股东的净利润为1457.1万元。归属于上市公司股东的扣除非经常性损益的净亏损为2699.04万元。基本每股收益为0.03元。此外，拟向全体股东每10股派发现金红利0.3元(含税)。报告期内公司积极推进临床短缺及易短缺产品的生产及销售，以及凉水河二街厂区验证进度，加快产品场地变更、技术转移以及GMP符合性检查等工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","300485","BK0046","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134152392","title":"太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1134152392","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134152392?lang=zh_cn&edition=full","pubTime":"2026-03-28 03:14","pubTimestamp":1774638866,"startTime":"0","endTime":"0","summary":"太阳制药宣布，其合作伙伴Philogen公司在软组织肉瘤领域开展的二期FLASH研究未能达到主要临床终点。与此同时，Philogen针对胶质母细胞瘤的二期GLIOSTAR试验同样未实现主要终点目标。\n尽管两项中期研究结果未达预期，Philogen仍表示将坚持推进GLIOSUN临床试验计划的执行。该决定彰显了公司对研发项目的持续投入与信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0239","300485","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622887272","title":"赛升药业：截至2026年3月20日，公司股东户数为32211","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622887272?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:36","pubTimestamp":1774496178,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)03月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月20日公司股东人数是多少？谢谢！赛升药业回复：您好，截至2026年3月20日，公司股东户数为32211。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600018973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","300485","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620732196","title":"赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620732196?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:32","pubTimestamp":1774017140,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，赛升药业报收于10.58元，较前一交易日下跌2.76%，最新总市值为50.96亿元。该股当日开盘10.88元，最高11.0元，最低10.58元，成交额达5750.63万元，换手率为1.95%。公司于近日披露《关于子公司撤回药品注册申请的公告》。公告显示，北京赛升药业股份有限公司子公司北京赛而生物药业有限公司近日收到国家药品监督管理局下发的《药品注册申请终止通知书》，同意撤回达格列净片的注册申请。此次撤回对公司研发工作及经营业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0046","300485","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620785067","title":"赛升药业(300485.SZ)子公司撤回一项药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620785067","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620785067?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:15","pubTimestamp":1773994526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司子公司北京赛而生物药业有限公司(简称“赛而生物”)近日收到了国家药品监督管理局下发的《药品注册申请终止通知书》，同意赛而生物撤回达格列净片的注册申请。公告显示，赛而生物于2025年3月向国家药品监督管理局递交达格列净片上市许可申请并获得受理，受政策法规变更等因素影响，需进一步完善申报资料，主动撤回本次申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0028","BK0012","300485","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150027399","title":"太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1150027399","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150027399?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:47","pubTimestamp":1773661653,"startTime":"0","endTime":"0","summary":"太阳制药工业有限公司宣布，美国食品药品监督管理局（FDA）已正式受理其ILUMYA®（Tildrakizumab-asmn）的补充生物制剂许可申请（sBLA），该药物拟用于治疗成人活动性银屑病关节炎。\nFDA针对ILUMYA®的sBLA审评截止日期定于2026年10月29日。这一监管里程碑标志着该药物在拓展适应症方面取得重要进展，有望为银屑病关节炎患者提供新的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0239","300485","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779067107022,"stockEarnings":[{"period":"1week","weight":-0.0522},{"period":"1month","weight":-0.1316},{"period":"3month","weight":-0.0977},{"period":"6month","weight":-0.239},{"period":"1year","weight":0.2405},{"period":"ytd","weight":-0.0397}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30334人(较上一季度减少1.64%)","perCapita":"9026股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":" 北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}